
Despite ongoing legal battles related to its talc products, Johnson & Johnson (NYSE:JNJ) stock has climbed over 23% year-to-date.
CNBC’s Jim Cramer on Thursday attributed the performance to investor confidence in Johnson & Johnson’s pharma strength and a shift in its legal approach, signaling that Wall Street may be moving past its longstanding concerns.